key: cord-0869048-6egk465y
authors: Mungmunpuntipantip, Rujittika; Wiwanitkit, Viroj
title: Correspondence on ‘CONVALESCENT plasma for COVID‐19’
date: 2021-09-13
journal: Eur J Clin Invest
DOI: 10.1111/eci.13677
sha: fdf2291ffdabdb50f72eed058a110d2654c06319
doc_id: 869048
cord_uid: 6egk465y

we would like to share ideas on the publication "CONVALESCENT plasma for COVID-19: A meta-analysis of clinical trials and real-world evidence [1]." Kloypan et al. reported that "7,118 patients received convalescent plasma (CP) and 7,780 patients received standard treatment" and found that "Patients treated with CP had a lower mortality rate than those treated with the standard treatment (1,590/7,118 vs. 2,004/7,780)." and concluded that "… CP use had a 31% reduced risk of all-cause mortality compared with standard treatment use… [1]".Kloypan et al. proposed that "Convalescent plasma (CP) use was associated with reduced risk of all-cause mortality in severe or critical COVID-19 patients [1]."

Dear Editor, We would like to share ideas on the publication 'CONVALESCENT plasma for COVID-19: A metaanalysis of clinical trials and real-world evidence 1 '. Kloypan et al. reported that '7,118 patients received convalescent plasma (CP) and 7,780 patients received standard treatment" and found that "Patients treated with CP had a lower mortality rate than those treated with the standard treatment (1,590/7,118 vs. 2,004/7,780)'. and concluded that '… CP use had a 31% reduced risk of all-cause mortality compared with standard treatment use… 1 '. Kloypan et al. proposed that 'Convalescent plasma (CP) use was associated with reduced risk of all-cause mortality in severe or critical COVID-19 patients 1 '. CP use might or might not useful for the management of COVID-19, but the safety is still an important consideration. 2 In the present report, Kloypan et al. compared and reported their result based on 'standard treatment'. Nevertheless, the exact 'standard treatment' is still inconclusive and recommendation at different chronological periods of COVID-19 outbreak is different. The standard treatment in different recruited trials is not the same (Table 1) . Various comparative treatments to CP therapy are observed. Different therapies might give benefit or cause a problem to the patient. Also, in some recruited reports in the meta-analysis, there is only historical control group. Furthermore, the protocols for CP therapy in different recruited studies are not the same and different doses and methods of administration might affect the outcome. Additionally, data from recruiting observational studies lack for confounding factor controls since those studies are not clinical trials or experiments. For those all 26 recruited observational studies, all lack for the comparative control group; therefore, the outcome of the patients who received CP therapy might or might significantly differ from that of patients who did not receive CP therapy in the same setting. Conclusively, there are many problems in the present meta-analysis. Also, there are various study designs for CP therapy. If it is intended to carry out a study with CP, an appropriate study design is necessary. The study should be a randomized placebocontrolled superiority multicentre clinical trial with an appropriate sample size. The protocol should be prepared in accordance with the SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) guidelines. Standard treatment should follow NIH COVID-19 Treatment Guidelines (https://www.covid 19tre atmen tguid elines.nih.gov/). The primary outcome is clinical status 30 days after intervention based on ordinal categories proposed by WHO Working Group on the Clinical Characterisation and Management of COVID-19.

CONVALESCENT plasma for COVID-19: a meta-analysis of clinical trials and real-world evidence

Convalescent plasma therapy in the treatment of COVID-19: some considerations: correspondence